Inflammation-regulating compositions and methods
The various embodiments provide a composition that provides local control over inflammation. The composition localizes the activities of the cytokine-neutralizing antibodies to the site of inflammation through covalent attachment to hydrophilic matrices. The various embodiments including a hydrophilic polymer, a ligand binding moiety covalently attached to the polymer, and optionally, a cellular adhesion peptide covalently attached to the polymer. The hydrophilic polymer may be a glycosaminoglycan such as hyaluronan. The cellular adhesion peptide may be a linear RGD peptide sequence covalently attached to the polymer. The ligand binding moiety may be a monoclonal antibody covalently attached to the polymer. The antibody may be selected from the group consisting of an anti-IL-1β, an anti-IL-6, an anti-TNF-α, and combinations thereof. The polymer functions as a substrate or matrix for cell migration and tissue regeneration. The RGD peptide functions to promote cellular proliferation, migration and attachment to the polymer. The monoclonal antibody functions to inhibit the inflammatory response.
1. A method for treating wounds, comprising:
administering to a chronic wound site a composition comprising:
a hyaluronan matrix; and
a monoclonal antibody directly conjugated to the hyaluronan matrix, wherein the antibody is selected from the group consisting of an anti-IL-1β, an anti-TNF-α, and combinations thereof.
2. The method of claim 1 , wherein the composition further comprises a linear arginine-glycine-aspartic acid (RGD) peptide covalently attached to the hyaluronan matrix.
3. The method of claim 1 , wherein the hyaluronan matrix is crosslinked to form a gel-like matrix.
4. The method of claim 1 , wherein the composition further comprises a peptide having SEQ ID NO:2 covalently attached to the hyaluronan matrix.
5. The method of claim 1 , wherein the composition further comprises a peptide having a sequence selected from the group consisting of SEQ ID NO. 1 and SEQ ID NO. 2 covalently attached to a polymer.
6. The method of claim 1 , wherein the composition is used to treat a wound selected from the group consisting of a pressure ulcer, a venous ulcer, and a diabetic ulcer.
7. The method of treatment of claim 1 , wherein composition is used to treat a dermal wound.
8. The method of treatment of claim 1 , wherein the composition is used to treat a wound in a patient having inflammatory bowel disease.
9. The method of treatment of claim 1 , wherein the composition is used to treat a wound in a patient having rheumatoid arthritis.
10. The method of treatment of claim 1 , wherein the composition is topically administered directly in a wound.
11. The method of treatment of claim 1 , wherein the composition is locally administered by hypodermic injection.
12. The method of treatment of claim 7 , wherein the dermal wound is a burn.